Molecular Pathogenesis and Targeted Therapy of Pancreatic Cancer

Annals of Surgical Oncology
Shinji Tanaka

Abstract

Accumulation of multiple genetic and/or epigenetic abnormalities is required for generation and progression of cancers, and the survival of cancer cells might depend on addiction to these abnormalities. Because disruption of such dependency on the abnormal molecules should cause the cancer cell death, so-called oncogene addiction is the rationale for molecular targeted therapy. Pancreatic cancer, especially pancreatic ductal adenocarcinoma, is one of the most lethal malignancies in humans, and remains a challenging problem in targeted therapy compared to other malignancies such as pancreatic neuroendocrine tumor. This review summarizes the molecular pathogenesis of pancreatic cancer on the basis of the recent studies of driver mutations including chromatin remodeling factors, and promising concepts "cancer stemness" and "stromal niche" for the strategy of novel targeted therapy.

References

Aug 26, 1998·Proceedings of the National Academy of Sciences of the United States of America·S TanakaK Sugimachi
Apr 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E Van CutsemD Von Hoff
Apr 6, 2006·Journal of the National Cancer Institute·Shinji TanakaShigeki Arii
Aug 9, 2006·Nature Clinical Practice. Oncology·I Bernard Weinstein, Andrew K Joe
Feb 7, 2007·Cancer Research·Chenwei LiDiane M Simeone
Apr 25, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Malcolm J MooreUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Oct 24, 2008·The New England Journal of Medicine·Christos S KarapetisJohn R Zalcberg
Dec 3, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian M WolpinCharles S Fuchs
Feb 28, 2009·Proceedings of the National Academy of Sciences of the United States of America·Hua TianFrederic J de Sauvage
Feb 19, 2010·Journal of the National Cancer Institute·Zeshaan A RasheedWilliam Matsui
Mar 27, 2010·Journal of the National Cancer Institute·Ken Garber
Jul 8, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philip A PhilipCharles D Blanke
Feb 11, 2011·The New England Journal of Medicine·Eric RaymondPhilippe Ruszniewski
Feb 11, 2011·The New England Journal of Medicine·James C YaoUNKNOWN RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group
May 31, 2011·Lancet·Audrey VincentMichael Goggins
Jul 2, 2011·Science·Christopher M HeaphyAlan K Meeker
Jul 14, 2011·Nature Reviews. Gastroenterology & Hepatology·Bo KongJörg Kleeff
Sep 29, 2011·Gastroenterology·Chenwei LiDiane M Simeone
Oct 5, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel D Von HoffManuel Hidalgo
Jan 12, 2012·Proceedings of the National Academy of Sciences of the United States of America·A Hunter ShainJonathan R Pollack
Jul 4, 2012·Proceedings of the National Academy of Sciences of the United States of America·Austin GurneyTimothy Hoey
Jul 10, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GonçalvesJ-L Raoul
Aug 1, 2012·Seminars in Oncology·Shinji Tanaka, Shigeki Arii
Sep 15, 2012·Cancer Cell·Christine M ArditoJens T Siveke
Oct 30, 2012·Nature·Andrew V BiankinSean M Grimmond
Mar 1, 2013·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Shunsuke MuramatsuShigeki Arii
Jul 11, 2013·Journal of the National Cancer Institute·Jianliang ZhangSteven N Hochwald
Oct 18, 2013·The New England Journal of Medicine·Daniel D Von HoffMarkus F Renschler
Nov 28, 2013·Proceedings of the National Academy of Sciences of the United States of America·Jun LiuJennifer L Harris
Dec 24, 2013·Cancer Discovery·Octavio A RomeroMontse Sanchez-Cespedes
Nov 1, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GonçalvesJ-L Raoul

❮ Previous
Next ❯

Citations

Feb 13, 2016·Acta histochemica·A GharibiJ A Kelber
Jun 1, 2016·Scientific Reports·Takaki FuruyamaMinoru Tanabe
Mar 31, 2018·Endocrine-related Cancer·Hiroki UedaShinji Tanaka
Oct 27, 2018·Journal of Cellular Physiology·Ali MohammadpourMohammad Momeni
Jun 28, 2019·The Journal of Gene Medicine·Fazhan WangXiangrong Song
Jul 14, 2017·Journal of Cellular Biochemistry·Matineh Barati BagherabadAmir Avan
May 15, 2020·Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen·A I DamanakisC J Bruns
Sep 13, 2019·Cell Communication and Signaling : CCS·Jiang-Jiang QinWei-Dong Zhang
Mar 21, 2019·Journal of Gastrointestinal Cancer·Marcus A AlvarezEvan S Glazer
Apr 16, 2015·Journal of Hepato-biliary-pancreatic Sciences·Shinji Tanaka
May 14, 2017·Journal of Materials Chemistry. B, Materials for Biology and Medicine·Guimiao LinKen-Tye Yong
Mar 12, 2021·Cellular Oncology (Dordrecht)·S Mazher HussainEvan S Glazer
Mar 26, 2021·Frontiers in Cell and Developmental Biology·Xinjian LiuGuangfu Li

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Islet Cell (Keystone)

Islet Cell Carcinoma or Pancreatic Neuroendocrine Tumours arise in the hormone producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on islet cell carcinoma in this feed.

Carcinoma, Islet Cell

Islet Cell Carcinoma or Pancreatic Neuroendocrine Tumours arises in the hormone producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on Islet Cell Carcinoma here.

Adenoma, Islet Cell

Islet Cell Adenoma arises in the islet cells, which are insulin producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on Islet Cell Adenoma here.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics and Chromatin (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin and its role in cancer epigenetics please follow this feed to learn more.

Addiction

This feed focuses mechanisms underlying addiction and addictive behaviour including heroin and opium dependence, alcohol intoxication, gambling, and tobacco addiction.

Cancer Epigenetics Chromatin Complexes (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin complexes and their role in cancer epigenetics.

Related Papers

Journal of Thoracic Disease
Dakai Xiao, Jianxing He
BioMed Research International
Jennifer Pasquier, Arash Rafii
Critical Reviews in Eukaryotic Gene Expression
Yu LiangCaifu Chen
© 2022 Meta ULC. All rights reserved